Kythera Acquires Rights to PGD2 Blocking Setipriprant for New Hair Loss Treatment

Collapse
X
 
  • Time
  • Show
Clear All
new posts

  • Jasari
    replied
    Never heard of this. What's the consensus? Promising?

    Leave a comment:


  • x4342
    replied
    I liked this line:

    "which together could enable KYTHERA to bring a new treatment to the very large and still highly unsatisfied hair loss market."


    Yep.

    Leave a comment:


  • It's2014ComeOnAlready
    replied
    They even finished a tolerability study on healthy men and women in Sept. 2013. The name of the doctor running the study was Daniela Baldoni! HAHA cannot make this stuff up.

    Leave a comment:


  • It's2014ComeOnAlready
    replied
    Also would add that the tolerability of this medication is the same to both men and women.

    Leave a comment:


  • It's2014ComeOnAlready
    replied
    Originally posted by burtandernie
    Ill be perfectly honest that I would like to see some study or a little more evidence before getting my hopes too high, but this is the news of the year that no one saw coming. If this isnt crazy positive news I dont know what is. The fact this is based off the PGD2 discovery really lends this a ton of credibility and they said they already have solid evidence this actually works. News of the year IMO
    There's a quote I posted from the Chief Medical Officer of Kythera saying that the compound works in the human hair pathway in all of their own studies. Also, I'm sure Cotsarelis had been using a similar formula in their follicular neogenesis trials. A study was published saying that pgd2 inhbits follicle neogenesis, so in order to actually run their trials, they would need a compound to inhibit pgd2. It must work, because Follica had run 2 trials, and still, a huge biopharmaceutical company wants to produce it.

    I wouldn't underestimate this kind of news. It could be the kind of news a lot of people looking for a new treatment have been waiting on.

    Leave a comment:


  • burtandernie
    replied
    Ill be perfectly honest that I would like to see some study or a little more evidence before getting my hopes too high, but this is the news of the year that no one saw coming. If this isnt crazy positive news I dont know what is. The fact this is based off the PGD2 discovery really lends this a ton of credibility and they said they already have solid evidence this actually works. News of the year IMO

    Leave a comment:


  • beetee
    replied
    Obviously going to take some time for this to follow its course and we don't know if it will be effective or not, but there's no doubt this goes in the good news category. I'll even put it in the very good news category.

    Leave a comment:


  • sdsurfin
    replied
    Just look up setipriprant clinical trials.

    Also, I'm not sure if any of this is worth getting excited about. there have been other compounds that do the same thing, such as OC000459 , which have been trialled by forum users without too much success. They seemed to sort of work but then stop working after a while. I think the whole PGD2 issue is only a part of the puzzle. Would definitely be good to talk to an expert about it.

    Leave a comment:


  • Sogeking
    replied
    Good news. However I hope we won't have to wait for 10+ years for this to come out.

    Things are finally heating up, a lot of treatments coming. It seems I was born too early...

    Leave a comment:


  • Jonathan
    replied
    Can you please link to the source?

    Leave a comment:


  • sdsurfin
    replied
    "All subjects completed the study. Both formulations were well tolerated, with headache the most frequently reported adverse event (25% of subjects), followed by flatulence (15%) and somnolence and fatigue (10%). The adverse event profile in men and women and between formulations was similar."

    hmmmmmm headaches? not so fun. I'll fart all day for a full head of hair though. These are some pretty high side effect percentages, I hope they do make a topical version.

    Leave a comment:


  • sdsurfin
    replied
    Frederick Beddingfield, MD, PhD

    Specialtyermatology
    Department Affiliation:Medicine, Dermatology
    Hospital Affiliation:Ronald Reagan UCLA Medical Center
    Phone:310-825-6911

    This guy is the head of research at Kythera. Someone should give him a call or set up a dermatology appointment with him (if you're in cali) and ask him why they think setipriprant has potential for hair loss, and how they plan to use it, topically or orally. Could be huge for forum people, if we can get this compound and figure out how to use it it might be a big help. Curiously, he also has worked for Allergan, the company developing bimatoprost. If I was in cali I'd definitely try to set up an appointment with him, he probably has a lot to say on hairloss.

    Leave a comment:


  • sdsurfin
    replied
    Actually the press release states that it is meant for oral use. Not positive that they wouldn't try to make it a topical too though. But yeah for real somebody get kane on this immediately, it has to be easier to come by than CB.

    Leave a comment:


  • EXprettyboy
    replied
    Cotsarellis' research found elevated pgd2 in bald scalps.

    Pgd2 receptors can be blocked by a safe clinically trialled drug.

    A company has just acquired a worldwide patent for this drug, after a period of curious silence from cotsarelis.

    Somebody wanna get Kane on this, IMMEDIATELY!!

    Leave a comment:


  • Tenma
    replied
    Originally posted by sdsurfin
    It all sounds good, the only thing that bothers me is that Actelion shelved the drug and never mentioned anything about hair. I know that Graza ad Cots have been trying to find the right PGD2 drug for a while though, maybe this is a good candidate.
    Because they werent rubbing the stuff onto their heads. They were after astma... now they will probably develop a topical and test different doses

    Its interesting that actelion will continue developing the stuff on their own.

    Leave a comment:

Working...